- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque psoriasis Moderate to severe hidradenitis suppurativa
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 341KB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 52KB)
Adalimumab – July 2022
Adalimumab: Injection 40 mg in 0.4 mL pre-filled pen, Injection 40 mg in 0.4 mL pre-filled syringe; Yuflyma®
Last updated
28 October 2022